Yusimry (Generic for adalimumab-aqvh)

Introducing Yusimry developed according to the adalimumab‑aqvh standard—a biologic agent that targets TNF‑alpha to reduce joint inflammation and disease progression in rheumatoid arthritis. Administered via pen‑injector, this formulation improves treatment adherence and patient comfort while delivering significant symptom reduction and enhanced quality of life.